NCT03195699
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations:
Breast Cancer Tissue:
Recruitment Status: Recruiting
Phase 1
Drug Category: Tyrosine-Kinase Inhibitor
Key Eligibility Criteria:
Gender: All
Age: 18 Years to 65 Years (Adult)
Location of Metastases:
Additional Notes:
Exclusions: Known active metastases in the central nervous system- see trial for details
https://ClinicalTrials.gov/show/NCT03195699